Oncoveda is a multi-discipline Cancer Research Center within Medical Diagnostic Laboratories, L.L.C. (MDL), a member of Genesis Biotechnology Group (GBG). Our research platform focuses on understanding tumor progression and response to chemotherapy as well as identifying and validating reliable cancer biomarkers and drug targets for cancer therapeutics. Our development platform translates these discoveries into clinical tests and small compound therapeutics to ultimately contribute to the early detection, monitoring, and treatment of urogenital cancers. ONCOVEDA is currently utilizing patient samples obtained by collaborating physicians and medical facilities, for use in an ongoing program to pursue FDA approval for our most advanced biomarker. We are currently seeking to establish additional collaborations with physicians and medical facilities to obtain patient samples for further investigations to validate potential biomarkers. We recently completed an ultra-high-throughput screen (uHTS) to validate a drug target in collaboration with VENENUM BioDesign, a member of Genesis Biotechnology Group (GBG) and are currently developing assays for two additional validated targets. Oncoveda is located conveniently in Hamilton, New Jersey, and is easily accessible to other academic research and medical centers, biotech companies, and pharmaceutical companies in the New York/New Jersey/Pennsylvania area. Our scientific staff has extensive clinical diagnostic industry, cancer research, and medical experience.